434 related articles for article (PubMed ID: 21084291)
1. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
[TBL] [Abstract][Full Text] [Related]
2. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A; Igarashi Y
Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
4. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.
Cartwright TA; Campos CR; Cannon RE; Miller DS
J Cereb Blood Flow Metab; 2013 Mar; 33(3):381-8. PubMed ID: 23168528
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
Clemens JJ; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
8. Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.
Obinata H; Gutkind S; Stitham J; Okuno T; Yokomizo T; Hwa J; Hla T
J Lipid Res; 2014 Dec; 55(12):2665-75. PubMed ID: 25293589
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
Kennedy PC; Zhu R; Huang T; Tomsig JL; Mathews TP; David M; Peyruchaud O; Macdonald TL; Lynch KR
J Pharmacol Exp Ther; 2011 Sep; 338(3):879-89. PubMed ID: 21632869
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.
Potteck H; Nieuwenhuis B; Lüth A; van der Giet M; Kleuser B
Cell Physiol Biochem; 2010; 26(1):67-78. PubMed ID: 20502006
[TBL] [Abstract][Full Text] [Related]
11. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
12. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
13. Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins.
Sarai K; Shikata K; Shikata Y; Omori K; Watanabe N; Sasaki M; Nishishita S; Wada J; Goda N; Kataoka N; Makino H
Am J Physiol Cell Physiol; 2009 Oct; 297(4):C945-54. PubMed ID: 19657053
[TBL] [Abstract][Full Text] [Related]
14. [Effects of sphingosine 1-phosphate on functions of T cell - review].
Huang WR; Wang LS; DA WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):718-22. PubMed ID: 16129068
[TBL] [Abstract][Full Text] [Related]
15. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
16. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.
Brinkmann V; Cyster JG; Hla T
Am J Transplant; 2004 Jul; 4(7):1019-25. PubMed ID: 15196057
[TBL] [Abstract][Full Text] [Related]
17. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
19. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
